Drug intelligence / Profile preview

carmustine + cisplatin + cytarabine + dacarbazine + hydroxyurea + prednisone + procarbazine + vincristine

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Intravenous, Oral, Intrathecal, Subcutaneous

Overview

This is a combination chemotherapy regimen consisting of eight different anticancer agents. The combination includes: - Carmustine: An alkylating agent that crosses the blood-brain barrier - Cisplatin: A platinum-based alkylating agent - Cytarabine: A pyrimidine nucleoside analog that inhibits DNA synthesis - Dacarbazine: An alkylating agent - Hydroxyurea: An antimetabolite that inhibits DNA synthesis - Prednisone: A corticosteroid with immunosuppressive and anti-inflammatory properties - Procarbazine: An alkylating agent - Vincristine: A vinca alkaloid that disrupts microtubule formation This intensive multi-agent regimen likely targets rapidly dividing cancer cells through multiple mechanisms to overcome resistance.

Targets

TUBB (Tubulin (alpha and beta subunits))GR (Glucocorticoid receptor)DNARNR (Ribonucleotide reductase)

Beyond the preview

Go deeper on carmustine + cisplatin + cytarabine + dacarbazine + hydroxyurea + prednisone + procarbazine + vincristine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carmustine + cisplatin + cytarabine + dacarbazine + hydroxyurea + prednisone + procarbazine + vincristine.

Explore the full profile